China-based Innovent Biologics has entered its seventh strategic collaboration with Eli Lilly, focusing on the global co-development of innovative drugs in oncology and immunology. Under the agreement, Innovent will receive an upfront payment of USD 350 million and is eligible for up to approximately USD 8.5 billion in development, regulatory and commercial milestone payments, plus tiered royalties on ex-Greater China net sales. The deal covers multiple early-stage assets, reflecting a trend towards deeper, earlier-stage collaboration between multinational and Chinese biopharma companies.

The partnership employs a stage-synergistic model: Innovent will lead drug discovery and proof-of-concept clinical studies in China through Phase II, while Eli Lilly gains exclusive global rights outside of Greater China to drive subsequent development and commercialisation. This structure leverages Innovent's R&D platform and clinical execution capabilities, while providing Eli Lilly with early-stage access to a portfolio of innovative molecules. The collaboration builds on a partnership between the two companies that began in 2015.

PharmCube's NextBiopharm® database shows that this is China's sixth-largest out-licensing transaction.  Click here to request a free trial for NextBiopharm®.